MDR-1 Expression and Deletions of Chromosomes 7 and 5(Q) Separately Indicate Adverse Prognosis in AML

References

• Bloomfield C D. Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. Leukemia 1992; 6(Suppl 4)65–67
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., Walters R. S., Smith T. L., Cork A., McCredie K. B., Freireich E. J. Therapy-related leukemia and myelodysplastic syndrome clinical, cytogenetic, and prognostic features. J Clin Oncol 1986; 12: 1748
   Google Scholar
• Pedersen-Bjergaard J., Philip P., Larsen S. O., Jensen G., Byrsting K. Chromosomal aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlym-phocytic leukemia. Blood 1990; 76: 1083–1091
   PubMed Web of Science ®Google Scholar
• List A. F. The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 1996; 10(Suppl 2)46–51
   Google Scholar
• Sikic B. I. Pharmacologic approaches to reversing multidrug resistance. Semin in Hematol 1997; 34(Suppl 5)40–47
   PubMed Web of Science ®Google Scholar
• Schoenlein P. V. Molecular cytogenetics of multiple drug resistance. Cytotechnology 1993; 12: 63–89
   PubMed Web of Science ®Google Scholar
• Tsuruo T., Sugimoto Y., Hamada H., Roninson I., Okumura M., Adachi K., Morishima Y., Ohno R. Detection of multidrug resistance markers, P-glycoprotein and mdr-1 mRNA, in human leukemia cells. Jpn J Cancer Res 1987; 78: 1415–1419
   PubMedGoogle Scholar
• Schneider E., Cowan K. H., Bader H., Toomey S., Schwartz G. N., Karp J. E., Burke P. J., Kaufman S. H. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995; 85: 186–193
   PubMed Web of Science ®Google Scholar
• Mitelman R, Heim S. Quantitative acute leukemia cytogenetics. Genes Chrom Cancer 1992; 5: 57–66
   PubMed Web of Science ®Google Scholar
• Nucifora G., Rowley J. D. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86: 1–14
   PubMed Web of Science ®Google Scholar
• Mrozek K., Heinonen K., de la Chapelle A., Bloomfield C D. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997; 94: 17–31
   Google Scholar
• Fairman J., Wang R. Y., Liang H., Zhao L., Saltman D., Liang J. C., Nagarajan L. Translocations and deletions of 5q13.1 in myelodysplasia and acute myelogenous leukemia: evidence for a novel critical locus. Blood 1996; 88: 2259–2266
   PubMed Web of Science ®Google Scholar
• Haferlach T. More individual markers are necessary for patients with acute myeloid leukemia (AML). Does cytomorphology or cytogenetics define the biological entity? Leukemia 1996; 10((Suppl.3))S5–S9
   Google Scholar
• Schoch C., Haase D., Fonatsch C., Haferlach T., Löffler H., Schlegelberger B., Hossfeld D. K., Becher R., Sauerland M. C., Heinecke A., Wormann B., Buchner T., Hiddeman W. The significance of trisomy 8 in de novo acute myeloid leukemia: the accompanying chromosome aberrations determine the prognosis. Br J Haematol 1997; 99: 605–611
   PubMed Web of Science ®Google Scholar
• Pinkel D., Straume T, Gray J. W. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci USA 1986; 83: 2938–2943
   Web of Science ®Google Scholar
• Bentz M., Cabot G., Moos M., Speicher M. R., Ganser A., Lichter P., Döhner H. Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood 1994; 83: 1922–1928
   PubMed Web of Science ®Google Scholar
• Fischer K., Fröhling S., Scherer S. W., McAllister Brown J., Scholl C., Stilgenbauer S., Tsui L. C., Lichter P., Dohner H. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood 1997; 89: 2036–2041
   PubMed Web of Science ®Google Scholar
• Büchner T, Hiddemann W., Wörmann B., Maschmeyer G., Heit W., Aul C., Heyll A., Löffler H., Gassmann H., Fiille H. H., Hellriegel K. P., Ludwig W. D., Lengfelder E., Lathan B., Emmerich B., Schaefer U. W., Sauerland M. C., Heinecke A. Chemotherapy intensity and long term outcome in AML, Büchner, et al. Acute Leukemias IV Springer-Verlag, Berlin Heidelberg 1994; 513–518
   Google Scholar
• Knauf W. U., Berdel W. E., Ho A. D., Kreuser E. D., Thiel E. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leukemia and Lymphoma 1994; 12: 421–425
   PubMed Web of Science ®Google Scholar
• Young I. T. Proof without prejudice: Use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977; 25: 935–938
   PubMed Web of Science ®Google Scholar
• Leith C. P., Chen I. M., Kopecky K. J., Appelbaum F. R., Head D. R., Godwin J. E., Weick J. K., Willman C L. Correlation of multidrug resistance (mdrl) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant mdr-/efflux+ and mdr+/efflux-cases. Blood 1995; 86: 2329–2342
   PubMed Web of Science ®Google Scholar
• Ivy S. P., Olshefski R. S., Taylor B. J., Patel K. M., Reaman G. H. Correlation of P-glycoprotein expression and function in childhood acute leukemia: a children's cancer group study. Blood 1996; 88: 309–318
   PubMed Web of Science ®Google Scholar
• Fonatsch C., Schaadt M., Kirchner H., Diehl V. A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines. Int J Cancer 1980; 26: 749–756
   PubMed Web of Science ®Google Scholar
• Kaplan E., Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457
   Web of Science ®Google Scholar
• Lamy T, Drenou B., Grulois I., Fardel O., Jacquelinet C., Goasguen J., Dauriac C., Amiot L., Bernard M., Fauchet R., Le Prise P. Y. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 1995; 9: 1549–1555
   PubMed Web of Science ®Google Scholar
• Leith C. P., Kopecky K. J., Godwin J., McConnell T, Slovak M. L., Chen I. M., Head D. R., Appelbaum F. R., Willman C L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (mdrl) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997; 89: 3323–3329
   PubMed Web of Science ®Google Scholar
• Willman C. L. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: Studies of the southwest oncology group leukemia research program. Semin in Hematol 1997; 34(Suppl 5)25–33
   PubMed Web of Science ®Google Scholar
• Filipits M., Suchmoel R. W., Zöchbauer S., Malayeri R., Pirker R. Clinical relevance of drug resistance genes in malignant diseases. Leukemia 1996; 10((Suppl.3))S10–S17
   PubMed Web of Science ®Google Scholar
• van den Heuvel-Eibrink M. M., van der Holt B., de Boekhorst P. A., Schoester M., Lowenberg B., Sonneveld P. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukemia. Br J Haematol 1997; 99: 76–83
   PubMed Web of Science ®Google Scholar
• Lohri A., van Hille B., Bacchi M, Fopp M., Joncourt F., Reuter J., Cerny T., Fey M. F., Hermann R. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase II alpha) in 57 newly diagnosed acute myeloid leukemias. Swiss Group of Clinical Research (SAKK). Eur J Haematol 1997; 59: 206–215
   PubMed Web of Science ®Google Scholar
• Schulz A., Engling P., Cao Q., Scheid C., Diehl V., Wickramanayake P. D. Lack of correlation between multi-drug resistance expression and clinical response to chemotherapy in patients with acute myeloid leukemia. Acute Leukemias VI;. Springer-Verlag, Berlin Heidelberg 1997; 587–592
   Google Scholar
• Broxterman H. J., Sonneveld P., Feller N., Ossenkoppele G. J., Wahrer D. C., Eekman C. A., Schoester M., Lankelma J., Pinedo H. M., Lowenberg B., Schuurhuis G. J. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 1996; 87: 4809–4816
   PubMed Web of Science ®Google Scholar
• Malayeri R., Filipits M., Suchomel R. W., Zöchbauer S., Lechner K., Pirker R. Multidrug resistance in leukemias and its reversal. Leukemia and Lymphoma 1996; 23: 451–458
   PubMed Web of Science ®Google Scholar
• den Boer M. L., Pieters R., Kazemier K. M., Rottier M. M.A., Zwaan C. M., Kaspers G. J.L., Janka-Schaub G. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092–2098
   PubMed Web of Science ®Google Scholar
• Filipits M., Pohl G., Stranzl T., Suchomel R. W., Scheper R. J., Jager U., Geissler K., Lechner K., Pirker R. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998; 91: 1508–1513
   PubMed Web of Science ®Google Scholar
• Wood P., Burgess R., MacGregor A., Yin L. A. P-glycoprotein expression in acute myeloid leukemia blast cells at diagnosis predict response to chemotherapy and survival. Br J Haematol 1994; 87: 509–514
   PubMed Web of Science ®Google Scholar
• Zöchbauer S., Haas O. A., Schwarzinger I., Lechner K., Pirker R. Multidrug resistance in acute myeloid leukemia with inversion in chromosome 16 or FAB M4Eo subtype. Lancet 1994; 344: 894
   PubMed Web of Science ®Google Scholar
• Del Poeta G., Stasi R., Aronica G., Venditti A., Cox M. C., Bruno A., Bucciscano F, Masi M., Tribalto M., Amadori S., Papa G. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996; 5: 1997–2004
   Google Scholar
• Minderman H., Vanhoefer U., Toth K., Yin M. B., Minderman M. D., Wrzosek C., Slovak M. L., Rustum Y. M. is not a substrate for multidrug resistance protein (MRP)-mediated drug efflux. Cytometry 1996; 25: 14–26
   PubMedGoogle Scholar
• Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• te Boekhorst P. A., de Leeuw K., Schoester M., Wittebol S., Nooter K., Hagemeijer A., Lowenberg B., Sonneveld P. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 1993; 82: 3157–3162
   PubMed Web of Science ®Google Scholar
• Amadori S., Venditti A., Del Poeta G., Stasi R., Buccisano F., Bruno A., Tamburini A., Cox M. C., Maffei L., Aronica Simone M.D., Adorno G., Masi M., Tribalto M., Papa G. Minimally differentiated acute myeloid leukemia (AML-M0): a distinct clinic-biologic entity with poor prognosis. Ann Heniatol 1996; 72: 208–215
   PubMed Web of Science ®Google Scholar
• Samdani A., Vijapurkar U., Grimm M. A., Spier C. S., Gorgan T. M., Glinsmann-Gibson B. J., List A. F. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leukemia Res 1996; 20: 175–180
   PubMed Web of Science ®Google Scholar
• Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., Rees J., Hann I., Stevens R., Burnett A., Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• Schiffer C. A., Lee E. J., Tomiyasu X, Wiernik P. H., Testa J. R. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73: 263–270
   PubMed Web of Science ®Google Scholar
• Datugue N., Payen C., Lafage-Pochitaloff M., et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia 1995; 9: 1491–1498
   PubMed Web of Science ®Google Scholar
• Keating M. J., Smith T. L., Kantarjian H., Cork A., Walters R., Trujillo J. M., McCredie K. B., Gehan E. A., Freireich E. J. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2: 403–412
   PubMed Web of Science ®Google Scholar
• Fenaux P., Preudhomme C., Lai J. L., Morel P., Beuscart R., Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukemia: a report on 283 cases. Br J Haematol 1989; 73: 61–67
   PubMed Web of Science ®Google Scholar
• Kadam P., Umerani A., Srivastava A., Masterson M., Lampkin B., Raza A. Combination of classical and interphase cytogenetics to investigate the biology of myeloid disorders: detection of masked monosomy 7 in AML. Leukemia Res 1993; 17: 365–374
   PubMed Web of Science ®Google Scholar
• Arif M., Tanaka K., Damodaran C., Asou H., Kyo T., Dohy H., Kamada N. Hidden monosomy 7 in acute myeloid leukemia and myelodysplastic syndrome detected by interphase fluorescence in situ hybridization. Leukemia Res 1996; 20: 709–716
   PubMed Web of Science ®Google Scholar
• Guerci A., Merlin J. L., Missoum N., Feldmann L., Marchal S., Witz F, Rose C., Guerci O. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995; 85: 2147–2153
   PubMed Web of Science ®Google Scholar